论文部分内容阅读
以生物素标记的HBV DNA作为探针,参照美国Enzo生化公司最新推荐的原位分子杂交技术程序,对26例石蜡包埋的伴(?)硬变肝癌组织内HBV DNA进行定位检测。结果显示,在14例(53.9％)癌周肝硬变组织内检出HBV DNA,主要分布于胞浆内,极少在核内出现。各阳性细胞内HBV DNA的杂交信号强弱不一,反映了病毒数量上的差异。阳性肝细胞的形态多无明显异型,而异型较明显的肝细胞不典型增生(LCD)则少有HBV DNA阳性杂交信号出现。本组无1例于肝癌细胞内检出HBV DNA。
Biotin-labeled HBV DNA was used as a probe, and HBV DNA was detected in 26 paraffin-embedded (?) hard-transplanted hepatocellular carcinoma tissues by referring to the latest in-situ molecular hybridization technique program recommended by Enzo Biochemical of the United States. The results showed that HBV DNA was detected in 14 cases (53.9%) of the cancerous pericardial cirrhosis, mainly in the cytoplasm and rarely in the nucleus. The hybridization signal of HBV DNA in each positive cell was different, reflecting the difference in the number of viruses. The morphology of positive hepatocytes did not show obvious abnormalities, while heterozygous obvious hepatocellular atypical hyperplasia (LCD) showed few positive hybridization signals of HBV DNA. None of the patients in this group had HBV DNA detected in liver cancer cells.